πŸ‡ΊπŸ‡Έ FDA
Patent

US 11512080

CRBN ligands and uses thereof

granted A61PA61P35/00

Quick answer

US patent 11512080 (CRBN ligands and uses thereof) held by Kymera Therapeutics, Inc. expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kymera Therapeutics, Inc.
Grant date
Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00